Quenching complement after stroke to protect the brain
Treatments studied
Part of Blood & lymphatic, Brain & nervous system, Heart & circulation clinical trials.
This trial tests a drug called EMPAVELI (also known as pegcetacoplan) to see if it can safely reduce harmful inflammation after a stroke. It is for people who had a clot in a large brain artery that was successfully removed within 24 hours.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old
- You had a stroke from a clot in a large artery in the front part of your brain, and it was successfully removed with a procedure
- You can be enrolled within 24 hours of the procedure, and the procedure happened within 24 hours of your stroke symptoms starting
- Your weight is at least 50 kg (about 110 pounds)
- You have been vaccinated against certain types of meningitis, pneumonia, and Hib, or are willing to get vaccinated soon after starting the study
- You are not pregnant, breastfeeding, or planning to become pregnant, and you agree to use birth control if needed
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine (glenzocimab) given along with standard clot-removal procedure for people who had a stroke with a large area of brain damage. The goal is to see if the medicine helps improve recovery.
This trial tests if giving a clot-busting drug (tenecteplase) directly into the brain artery after a successful clot-removal procedure can improve outcomes for people with a major stroke. It is for patients who had a large vessel blockage and received endovascular thrombectomy within 24 hours of symptoms starting.
This trial tests whether giving a clot-busting drug (tenecteplase) before transferring you to a hospital that can do a procedure to remove the clot improves outcomes for people who had a stroke up to 24 hours earlier. You may qualify if you have a blockage in a large artery in the front of your brain and can still get the procedure.
This Phase 2 trial tests whether the study medicine (LT3001) is safe and improves outcomes for people with an acute ischemic stroke who are getting a procedure to remove a clot (EVT). It aims to help certain patients who have a specific brain scan pattern soon after stroke symptoms start.
This trial tests if removing a large blood clot from the brain up to 3 days after a stroke improves recovery compared to standard medical care alone. It is for patients who have a severe stroke and are otherwise healthy enough for the procedure.
This study tests a neuroprotective treatment (a medication designed to protect brain cells) in patients with acute ischemic stroke—a stroke caused by a blood clot. The goal is to see if the treatment can reduce brain damage and improve recovery when given within 48 hours of stroke symptoms.
Hear when a new Acute Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.